Invention Grant
US08192935B2 Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer as related to MetAP2 expression
有权
评估与MetAP2表达相关的卵巢癌顺铂耐药性，疾病进展和治疗效果的方法
- Patent Title: Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer as related to MetAP2 expression
- Patent Title (中): 评估与MetAP2表达相关的卵巢癌顺铂耐药性，疾病进展和治疗效果的方法
-
Application No.: US12711068Application Date: 2010-02-23
-
Publication No.: US08192935B2Publication Date: 2012-06-05
- Inventor: Samer Al-Murrani
- Applicant: Samer Al-Murrani
- Applicant Address: US PA University Park
- Assignee: The Penn State Research Foundation
- Current Assignee: The Penn State Research Foundation
- Current Assignee Address: US PA University Park
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; G01N33/53 ; C12P19/34
Abstract:
The invention provides methods for predicting whether an ovarian cancer patient's tumor will be resistant to chemotherapy. The invention also provides methods for monitoring the effectiveness of treatment, particularly a chemotherapeutic treatment, in a patient treated for ovarian cancer. The invention further provides methods for treating ovarian cancer, by reducing chemotherapeutic drug resistance in said cells. In addition, the invention provides methods of screening compounds to identify tumor cell growth inhibitors in tumor cells resistant to conventional chemotherapeutic treatment regimes.
Public/Granted literature
- US20100221731A1 Methods for assessing MetAP2 Resistance, Disease Progression, and Treatment Efficacy in Ovarian Cancer Public/Granted day:2010-09-02
Information query
